查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1649462

重症肌无力治疗市场：预测（2025-2030）

Myasthenia Gravis Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

重症肌无力治疗市场预计将以 7.14% 的复合年增长率成长，到 2025 年达到 19.73 亿美元，到 2030 年达到 27.85 亿美元。

重症肌无力是一种慢性神经肌肉疾病，其特征是随意肌无力，主要由神经和肌肉之间传递的信号出现问题引起。重症肌无力的治疗方法包括多种药物治疗，包括输血、类固醇和肌肉强化药物，以及手术介入。重症肌无力是一种影响人体随意肌的慢性自体免疫疾病。近年来，全球自体免疫疾病病例显着增加，尤其是老年族群。此外，预计预测期内製药业研发的不断加强将进一步推动市场成长。

推动重症肌无力治疗市场的因素：

  • 自体免疫疾病盛行率不断增加：全球自体免疫疾病盛行率不断增加是推动重症肌无力治疗市场扩张的关键因素。当免疫系统错误地攻击健康组织时，就会发生自体免疫疾病，而重症肌无力则会破坏肌肉和神经之间的沟通。根据牛津大学的最新资料，全球约有10%的人口受到这些疾病的影响，其中女性为13%，男性为7%。

影响重症肌无力治疗市场的地理趋势：

  • 北美显着成长：预计预测期内北美地区将占据重症肌无力治疗市场的大部分份额。这一成长主要得益于美国和加拿大等国家的製药技术和研发生态系统的进步。美国是药品和技术的主要生产国，支持了重症肌无力治疗市场的扩大。

此外，旨在加强药品研究和开发的政府措施预计将对市场成长做出重大贡献。该地区神经系统疾病的高发性推动了对有效治疗的需求，预计未来几年阿兹海默症症等疾病将影响数百万人。总而言之，由于全球自体免疫疾病盛行率不断上升、人们对早期诊断和治疗方案的认识不断提高、製药技术的进步以及政府（尤其是北美政府）的支持性倡议，重症肌无力治疗市场预计将大幅增长，推动这一重要医疗保健领域的创新。

为什么要购买这份报告？

  • 深刻分析：获得深入的市场洞察，涵盖主要和新兴地区，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响市场的未来发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问公司、中小企业和大型企业都有益且具有成本效益。

它有什么用途？

产业与市场分析、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2030 年的实际资料和预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争定位、策略与市场占有率分析
  • 各地区（包括细分市场和国家）的收益成长和预测分析
  • 公司概况（策略、产品、财务、主要发展等）

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 研究过程

第三章执行摘要

  • 主要发现

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章 重症肌无力治疗市场（依应用）

  • 介绍
  • 药物
  • 外科手术
  • 其他的

6. 重症肌无力治疗市场（依最终用户划分）

  • 介绍
  • 医院
  • 诊所
  • 其他的

7. 重症肌无力治疗市场（按地区）

  • 介绍
  • 北美洲
    • 按应用
    • 按最终用户
    • 按国家
  • 南美洲
    • 按应用
    • 按最终用户
    • 按国家
  • 欧洲
    • 按应用
    • 按最终用户
    • 按国家
  • 中东和非洲
    • 按应用
    • 按最终用户
    • 按国家
  • 亚太地区
    • 按应用
    • 按最终用户
    • 按国家

第八章 竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第九章 公司简介

  • UCB SA
  • AstraZeneca
  • Johnson & Johnson
  • Alexion Pharmaceuticals, Inc
  • Argenx
  • Merck KGaA
  • F.Hoffmann-La Roche Ltd
  • Astellas Pharma Inc.
  • Bayer AG
  • Sanofi
  • Amneal Pharmaceuticals LLC.
  • Zydus Group
  • Hikma Pharmaceuticals PLC
简介目录
Product Code: KSI061617238

The myasthenia gravis treatment market is estimated to grow at a CAGR of 7.14%, from US$2.785 billion by 2030 to US$1.973 billion in 2025.

Myasthenia gravis is a chronic neuromuscular disease characterized by weakness in the voluntary muscles, primarily caused by issues with the signals sent between nerves and muscles. Treatment options for myasthenia gravis include various medications and surgical interventions, such as blood transfusions, steroids, and muscle strengtheners. The global myasthenia gravis treatment market is anticipated to experience significant growth due to the increasing prevalence of autoimmune diseases.As a chronic autoimmune disorder, myasthenia gravis affects the voluntary muscles of the body. The rise in global cases of autoimmune diseases has been notable in recent years, particularly among older adults. Additionally, ongoing research and development within the pharmaceutical sector are expected to further drive market growth during the forecast period.

Drivers of the Myasthenia Gravis Treatment Market:

  • Increasing Prevalence of Autoimmune Disorders: The growing global incidence of autoimmune disorders is a key factor fueling the expansion of the myasthenia gravis treatment market. Autoimmune disorders occur when the immune system mistakenly attacks healthy tissues, and myasthenia gravis disrupts communication between muscles and nerves. Recent data from the University of Oxford indicates that approximately 10% of the global population is affected by these diseases, with 13% of women and 7% of men impacted.

Geographical Trends Shaping the Myasthenia Gravis Treatment Market:

  • Significant Growth in North America: The North American region is projected to hold a substantial share of the myasthenia gravis treatment market during the forecast period. This growth is primarily driven by advancements in pharmaceutical technologies and research and development ecosystems in countries like the USA and Canada. The USA is a leading producer of pharmaceutical drugs and technologies, which supports market expansion for myasthenia gravis treatments.

Moreover, government initiatives aimed at enhancing pharmaceutical research and development are expected to significantly contribute to market growth. The high prevalence of neurological disorders in this region further drives demand for effective treatments, with projections indicating that there will be millions affected by conditions like Alzheimer's disease in the coming years.In summary, the myasthenia gravis treatment market is poised for substantial growth due to rising prevalence rates of autoimmune disorders globally, increased awareness about early diagnosis and treatment options, advancements in pharmaceutical technologies, and supportive governmental initiatives-particularly within North America-that foster innovation in this critical healthcare sector.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Myasthenia Gravis Treatment market is segmented and analyzed as follows:

By Application

  • Medication
  • Pyridostigmine
  • Cyclosporine
  • Azathioprine
  • Surgery
  • Other

By End User

  • Hospitals
  • Clinics
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • Spain
  • United Kingdom
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • Australia
  • India
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. MYASTHENIA GRAVIS TREATMENT MARKET BY APPLICATION

  • 5.1. Introduction
  • 5.2. Medication
  • 5.3. Surgery
  • 5.4. Other

6. MYASTHENIA GRAVIS TREATMENT MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Hospital
  • 6.3. Clinics
  • 6.4. Others

7. MYASTHENIA GRAVIS TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Application
    • 7.2.2. By End User
    • 7.2.3. By Country
      • 7.2.3.1. United States
      • 7.2.3.2. Canada
      • 7.2.3.3. Mexico
  • 7.3. South America
    • 7.3.1. By Application
    • 7.3.2. By End User
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
      • 7.3.3.2. Argentina
      • 7.3.3.3. Others
  • 7.4. Europe
    • 7.4.1. By Application
    • 7.4.2. By End User
    • 7.4.3. By Country
      • 7.4.3.1. Germany
      • 7.4.3.2. Spain
      • 7.4.3.3. United Kingdom
      • 7.4.3.4. France
      • 7.4.3.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. By Application
    • 7.5.2. By End User
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
      • 7.5.3.2. South Africa
      • 7.5.3.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. By Application
    • 7.6.2. By End User
    • 7.6.3. By Country
      • 7.6.3.1. China
      • 7.6.3.2. Japan
      • 7.6.3.3. Australia
      • 7.6.3.4. India
      • 7.6.3.5. South Korea
      • 7.6.3.6. Indonesia
      • 7.6.3.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. UCB S.A.
  • 9.2. AstraZeneca
  • 9.3. Johnson & Johnson
  • 9.4. Alexion Pharmaceuticals, Inc
  • 9.5. Argenx
  • 9.6. Merck KGaA
  • 9.7. F.Hoffmann-La Roche Ltd
  • 9.8. Astellas Pharma Inc.
  • 9.9. Bayer AG
  • 9.10. Sanofi
  • 9.11. Amneal Pharmaceuticals LLC.
  • 9.12. Zydus Group
  • 9.13. Hikma Pharmaceuticals PLC